Hiring Postdoc for Study of Proton Biology

We are seeking an applicant with training and research experience in molecular biology/oncology to carry out an exciting NCI-funded, multidisciplinary project aimed at elucidating the biological effects of proton radiation in cancers. Specifically, we seek to characterize genome wide DNA damage caused by proton radiation and damage responses as a function of tumor genotype. Combinations of protons with targeted drugs will be examined as well. We hope that discovery of biomarkers predicting proton sensitivity will impact the care of cancer patients within the next few years.

Expertise in molecular biology, genomics/bioinformatics, radiation biology, or/and DNA repair is desirable.

Applicants must have a Ph.D. and/or M.D., appropriate research experience, strong organizational, interpersonal, communication, and computer skills and be excited to work in a dynamic team environment.

LinkedIn

MGH Jobs Site

New Project on High-Throughput Screening of 3D Pancreatic Cancer Models

We are thankful and honored to have received an award from the MGH Warshaw Institute to establish a high-throughput screening platform for 3-dimensional models of pancreatic cancers. We will test novel combination treatments that include proton radiation. Our work will provide a resource for other investigators and critical preliminary data for future investigations into biologically optimized proton radiation.

July 2021

Henning Willers, MD & Chris Ott, PhD, Co-PIs
MGH Dept of Radiation Oncology & Center for Cancer Research

Welcome DF/HCC SPARC Summer Student!

We are thrilled to welcome Emily for an in-person lab internship. So nice to be (slowly) getting away from the virtual world we were stuck in for too long. Emily participates in a Summer Program to Advance Research Careers (SPARC), a 12-week intensive research experience focused on emerging technologies in cancer and cancer disparities. She’ll learn about our robotic high-throughput screening project with radiation and targeted drugs!

https://www.dfhcc.harvard.edu/research/cancer-disparities/students/sparc/

May 2021 – Looking for a Lab Technician

We offer a position in an exciting, topical, and fast-moving field of translational cancer research. The objective of our studies is to advance precision medicine concepts in the treatment of cancer patients with radiation and specifically proton radiation. The project is centered on whole exome sequencing of tumor tissues from patients and correlative lab studies to characterize the cellular response of genomically characterized tumor cells and tissues to radiation. Collectively the studies will identify predictive biomarkers and mechanisms of enhanced sensitivity of tumors to proton radiation. Techniques include handling of tissues specimens from patients, DNA extraction, mammalian cell culture, PCR, immunofluorescence microscopy, Western blotting, and others. We seek a highly motivated individual with a strong interest in an academic career and prior wet lab experience. The research project is institutionally funded and part of the Radiation Biomarker Research Program in the Department of Radiation Oncology.

Change this Subheading

Image Box Title

Change this description

So many things happened

Should have updated this page a long time ago. But in short:

  1. Proud to have published with Iris Eke, MD PhD, Stanford, a Springer book on molecular targeted radiosensitizers which you can find here .
  2. We welcomed Aliza Rosenkranz as a research technician to our lab – she will study combining radiation with KRAS G12C inhibition!
  3. We finally completed our paper studying the replication stress phenotype of KRAS mutant tumor cells, led by co-first authors Tara Al Zubaidi and Fiete Gehrisch. Published by Scientific Reports here.
  4. Again overhauling our website in preparation for the launch of our Radiation Biology Research Program – stay tuned!

New Project July 2018

We are thrilled to have received funding from the NCI for high-throughput screening and validation of targeted radiosensitizers and biomarker discovery. We are looking forward to collaborating with other investigators in the Preclinical Chemo-Radiotherapy Testing Consortium (PCRTC), which is tasked with accelerating the pace by at which molecular targeted drug/radiation combinations with greater efficacy than in the past are identified.